An observational study in Non-Small Cell Lung Cancer, sponsored by Bristol-Myers Squibb. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-21.
Sponsored by Bristol-Myers Squibb · Observational
This study uses existing medical records to better understand how immunotherapy is used in people in Europe and Canada with non-small cell lung cancer (NSCLC) who undergo surgery. It looks at participant characteristics, treatments received before and after surgery, and outcomes such as survival.
6,488 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,632 are open to participants now.
This study's planned enrollment of 300 is above the median of 161 across 949 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
Adults diagnosed with non-metastatic stage IIA-IIIB non-small cell lung cancer (NSCLC) receiving neoadjuvant or perioperative immunotherapy in routine clinical practice across Europe and Canada.
Exclusion Criteria:
Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received neoadjuvant immunotherapy prior to surgery but did not initiate adjuvant immunotherapy post-surgery.
Biological: nivolumab · Biological: pembrolizumab · Biological: durvalumab
Participants with resected non-small-cell lung cancer (NSCLC) stage IIA-IIIB who received immunotherapy before surgery and continued the same immunotherapy after surgery (adjuvant phase).
Biological: nivolumab · Biological: pembrolizumab · Biological: durvalumab
As per product label
As per product label
As per product label
Number of participants with pathological complete response after neoadjuvant immunotherapy and surgical resection.
Pathological complete response (pCR) is defined as 0% residual viable tumor cells in the primary tumor and all sampled regional lymph nodes following neoadjuvant immunotherapy and surgical resection.
Time frame: Up to 14 months
Number of participants with major pathological response after neoadjuvant immunotherapy and surgical resection.
Major pathological response (MPR) is defined as ≤10% residual viable tumor cells in the primary tumor and all sampled regional lymph nodes following neoadjuvant immunotherapy and surgical resection.
Time frame: Up to 14 months
Number of participants with post-operative complications following surgical resection
Post-operative complications include infection, pneumonia, respiratory failure requiring assisted ventilation or intubation, immune-related pneumonitis, myocardial infarction, atrial fibrillation, cardiac failure, unplanned intensive care unit admission, stroke, acute renal failure, bronchopleural fistula, empyema, re-operation, prolonged hospitalization, prolonged air leak greater than 5 days, in-hospital death, 30-day death, and 90-day death.
Time frame: Up to 90 days
Number of participants by surgical resection margin status
Surgical resection margin status following surgery will be categorized as R0 (no residual tumor), R1 (microscopic residual tumor), or R2 (macroscopic residual tumor).
Time frame: Up to 14 months
Number of participants by surgical resection type
Surgical resection type will be categorized as lobectomy, bilobectomy, segmentectomy, wedge resection, pneumonectomy, or sleeve resection.
Time frame: Day 1
Number of participants by surgical approach
Surgical approach will be categorized as open thoracotomy, video-assisted thoracoscopic surgery (VATS), or robotic-assisted surgery.
Time frame: Day 1
Number of participants with all-cause mortality within 90 days after surgery
All-cause mortality occurring during hospitalization or within 90 days after surgical resection will be summarized.
Time frame: Up to 90 days
Overall survival from surgical resection
Overall survival (OS) is defined as the time from surgical resection to death from any cause.
Time frame: Up to 46 months
Event-free survival from surgical resection
Event-free survival (EFS) is defined as the time from surgical resection to the first occurrence of disease recurrence or progression after surgery, or death from any cause.
Time frame: Up to 46 months
Number of participants initiating adjuvant immunotherapy after surgery
Adjuvant immunotherapy includes pembrolizumab, durvalumab, or nivolumab.
Time frame: Up to 14 months
Time (days) from surgery to initiation of adjuvant immunotherapy
Time frame: Up to 14 months
Number of participants receiving post-surgical systemic and local therapies
Post-surgical therapies received during follow-up will be summarized and include adjuvant immunotherapy, adjuvant chemotherapy, radiotherapy, targeted therapy, and advanced or metastatic treatments.
Time frame: Up to 46 months
Length of hospital stay (days) following surgical resection
Time frame: Up to 90 days
Number of participants with immune-mediated adverse events (AEs) during neoadjuvant immunotherapy
Time frame: Up to 22 months
Plan to share: No
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung→
Bristol-Myers Squibb